Celaid Therapeutics has been selected as one of the eight most outstanding projects in the field of innovative medical and biotechnology in the "Boehringer Ingelheim Innovation Prize" organized by Nippon Boehringer Ingelheim Co., Ltd.. Celaid will now take the stage at the pitch contest as a finalist, which will be held on September 28, 2022.
Website: Nippon Boehringer Ingelheim Co., Ltd.
＜ Pitch contest ＞
|Celaid Therapeutics Inc.||Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells for allogeneic HSCT with Hematologic malignancies|
|C4U Corporation||NextGen CRISPR-Cas3 Gene Editing Technology|
|FerroptoCure Inc.||Anti-cancer drug inducing “Ferroptosis”|
|Gap Junction Therapeutics, Inc.||Development of gene therapy and drugs for hearing loss|
|miibio, Inc||A photo-controllable gene therapy|
|Rebirthel Co., Ltd.||Technologies for allogeneic regenerated T cell therapy derived from iPS cells|
|siDreaMed(tentative name)||Development and commercialization of siRNAs that suppress only disease-causing genes with single nucleotide mutations.|
|Tohoku University(Dr. Ichiro Kawahata)||Development of peptide drug for Lewy body diseases|